FDA has been closing out the summer with a rash of approvals, including three novel agents. Novartis AG's Kymriah, the first CAR-T cell therapy, may have dominated headlines, but FDA also approved a new antibiotic (The Medicines Co.s Vabomere) and benznidazole, the first Chagas disease therapy.
FDA also cleared the return to market of Pfizer Inc.'s Mylotarg, a hematologic oncology agent that was withdrawn in 2000, and a new first-line indication for AstraZeneca PLC's...